Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Revenue (2016 - 2026)

Intellia Therapeutics has reported Revenue over the past 12 years, most recently at $15.0 million for Q1 2026.

  • Quarterly Revenue fell 9.5% to $15.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $66.1 million through Mar 2026, up 45.04% year-over-year, with the annual reading at $67.7 million for FY2025, 16.92% up from the prior year.
  • Revenue was $15.0 million for Q1 2026 at Intellia Therapeutics, down from $23.0 million in the prior quarter.
  • Over five years, Revenue peaked at $28.9 million in Q1 2024 and troughed at -$1.9 million in Q4 2023.
  • The 5-year median for Revenue is $13.6 million (2022), against an average of $13.5 million.
  • Year-over-year, Revenue surged 4322.0% in 2022 and then tumbled 114.12% in 2023.
  • A 5-year view of Revenue shows it stood at $13.6 million in 2022, then plummeted by 114.12% to -$1.9 million in 2023, then surged by 771.57% to $12.9 million in 2024, then skyrocketed by 78.79% to $23.0 million in 2025, then plummeted by 34.62% to $15.0 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Revenue are $15.0 million (Q1 2026), $23.0 million (Q4 2025), and $13.8 million (Q3 2025).